BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 16222156)

  • 1. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Kocijancic I; Segedin B; Vrankar M
    Anticancer Drugs; 2005 Nov; 16(10):1129-34. PubMed ID: 16222156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
    Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
    J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Strojan P
    J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
    Xiong JP; Feng M; Qiu F; Xu J; Tao QS; Zhang L; Xiang XJ; Zhong LX; Yu F; Ma XT; Gong WY
    Lung Cancer; 2008 May; 60(2):208-14. PubMed ID: 18023915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
    Kovac V; Zwitter M; Rajer M; Marin A; Debeljak A; Smrdel U; Vrankar M
    Anticancer Drugs; 2012 Feb; 23(2):230-8. PubMed ID: 22027538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma.
    Froudarakis ME; Pataka A; Pappas P; Anevlavis S; Argiana E; Nikolaidou M; Kouliatis G; Pozova S; Marselos M; Bouros D
    Cancer; 2008 Nov; 113(10):2752-60. PubMed ID: 18823054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
    Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
    Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
    Xiong JP; Zhang L; Zhong LX; Qiu F; Guo YL; Lian HY; Luo H
    Ai Zheng; 2006 Aug; 25(8):995-8. PubMed ID: 16965681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
    Zwitter M; Kovac V; Rajer M; Vrankar M; Smrdel U
    Anticancer Drugs; 2010 Jul; 21(6):662-8. PubMed ID: 20453635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
    Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
    Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
    Artal-Cortés A; Martínez-Trufero J; Herrero A; Puértolas T; Alonso V; Corral M; Ceballos C; Maurel J; Antón A
    Anticancer Drugs; 2003 Feb; 14(2):111-8. PubMed ID: 12569297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
    Antón A; Díaz-Fernández N; González Larriba JL; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
    Lung Cancer; 1998 Nov; 22(2):139-48. PubMed ID: 10022221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
    Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
    Bourgeois H; Billiart I; Chabrun V; Chieze S; Lemerre D; Germain T; Ferrand V; Meurice JC; Daban A; Tourani JM
    Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
    Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.